| Authors: |
Le Saux O; 'Cancer Immune Surveillance and Therapeutic Targeting' Laboratory, Cancer Research Center of Lyon, INSERM 1052-CNRS 5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, 69008, Lyon, France.; Lyon University, Université Claude Bernard Lyon 1, Centre Léon Bérard, 69008, Lyon, France.; National Investigators Group for Ovarian and Breast Cancer Studies, Paris, France.; Department of Medical Oncology, Centre Léon Bérard, 69008, Lyon, France., Ardin M; 'Cancer Immune Surveillance and Therapeutic Targeting' Laboratory, Cancer Research Center of Lyon, INSERM 1052-CNRS 5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, 69008, Lyon, France.; Lyon University, Université Claude Bernard Lyon 1, Centre Léon Bérard, 69008, Lyon, France., Berthet J; 'Cancer Immune Surveillance and Therapeutic Targeting' Laboratory, Cancer Research Center of Lyon, INSERM 1052-CNRS 5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, 69008, Lyon, France.; Lyon University, Université Claude Bernard Lyon 1, Centre Léon Bérard, 69008, Lyon, France.; Lyon Immunotherapy for Cancer Laboratory (LICL), Cancer Research Center of Lyon, Centre Léon Bérard, 69008, Lyon, France., Barrin S; Lyon Immunotherapy for Cancer Laboratory (LICL), Cancer Research Center of Lyon, Centre Léon Bérard, 69008, Lyon, France., Bourhis M; Université Paris Cité, Inserm, PARCC, F-75015, Paris, France., Cinier J; 'Cancer Immune Surveillance and Therapeutic Targeting' Laboratory, Cancer Research Center of Lyon, INSERM 1052-CNRS 5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, 69008, Lyon, France.; Lyon University, Université Claude Bernard Lyon 1, Centre Léon Bérard, 69008, Lyon, France., Lounici Y; 'Cancer Immune Surveillance and Therapeutic Targeting' Laboratory, Cancer Research Center of Lyon, INSERM 1052-CNRS 5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, 69008, Lyon, France.; Lyon University, Université Claude Bernard Lyon 1, Centre Léon Bérard, 69008, Lyon, France., Treilleux I; Department of Anatomopathology, Centre Léon Bérard, 69008, Lyon, France., Just PA; Department of Anatomopathology, AP-HM, Marseille, France., Bataillon G; Department of Anatomopathology, University hospital of Toulouse, Toulouse, France., Savoye AM; National Investigators Group for Ovarian and Breast Cancer Studies, Paris, France.; Department of Medical Oncology, Institut Jean Godinot, Reims, France., Mouret-Reynier MA; National Investigators Group for Ovarian and Breast Cancer Studies, Paris, France.; Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France., Coquan E; National Investigators Group for Ovarian and Breast Cancer Studies, Paris, France.; Department of Medical Oncology, Centre François Baclesse, Caen, France., Derbel O; Department of Medical Oncology, Hôpital Privé Jean Mermoz, Lyon, France., Jeay L; Keen Eye Technologies-Paris, France, now Tribun Health, Paris, France., Bouizaguen S; Keen Eye Technologies-Paris, France, now Tribun Health, Paris, France., Labidi-Galy I; Department of Oncology, Hôpitaux universitaires de Genève, Faculty of Medecine, Center of Translational Research in Onco-Hematology, Swiss Cancer Center Leman, Geneva, Switzerland., Tabone-Eglinger S; Human Biological Resources, Centre Léon Bérard, 69008, Lyon, France., Ferrari A; Synergie Lyon Cancer, Gilles Thomas Bioinformatics Platform, Centre Léon Bérard, CEDEX 08, F-69373, Lyon, France., Thomas E; Synergie Lyon Cancer, Gilles Thomas Bioinformatics Platform, Centre Léon Bérard, CEDEX 08, F-69373, Lyon, France., Ménétrier-Caux C; 'Cancer Immune Surveillance and Therapeutic Targeting' Laboratory, Cancer Research Center of Lyon, INSERM 1052-CNRS 5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, 69008, Lyon, France.; Lyon University, Université Claude Bernard Lyon 1, Centre Léon Bérard, 69008, Lyon, France.; Lyon Immunotherapy for Cancer Laboratory (LICL), Cancer Research Center of Lyon, Centre Léon Bérard, 69008, Lyon, France., Tartour E; Université Paris Cité, Inserm, PARCC, F-75015, Paris, France., Galy-Fauroux I; Université Paris Cité, Inserm, PARCC, F-75015, Paris, France., Stern MH; Inserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.) Team, Institut Curie, PSL Research University, 75005, Paris, France., Terme M; Université Paris Cité, Inserm, PARCC, F-75015, Paris, France., Caux C; 'Cancer Immune Surveillance and Therapeutic Targeting' Laboratory, Cancer Research Center of Lyon, INSERM 1052-CNRS 5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, 69008, Lyon, France.; Lyon University, Université Claude Bernard Lyon 1, Centre Léon Bérard, 69008, Lyon, France.; Lyon Immunotherapy for Cancer Laboratory (LICL), Cancer Research Center of Lyon, Centre Léon Bérard, 69008, Lyon, France., Dubois B; 'Cancer Immune Surveillance and Therapeutic Targeting' Laboratory, Cancer Research Center of Lyon, INSERM 1052-CNRS 5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, 69008, Lyon, France. bertrand.dubois@lyon.unicancer.fr.; Lyon University, Université Claude Bernard Lyon 1, Centre Léon Bérard, 69008, Lyon, France. bertrand.dubois@lyon.unicancer.fr.; Lyon Immunotherapy for Cancer Laboratory (LICL), Cancer Research Center of Lyon, Centre Léon Bérard, 69008, Lyon, France. bertrand.dubois@lyon.unicancer.fr., Ray-Coquard I; Lyon University, Université Claude Bernard Lyon 1, Centre Léon Bérard, 69008, Lyon, France. isabelle.ray-coquard@lyon.unicancer.fr.; National Investigators Group for Ovarian and Breast Cancer Studies, Paris, France. isabelle.ray-coquard@lyon.unicancer.fr.; Department of Medical Oncology, Centre Léon Bérard, 69008, Lyon, France. isabelle.ray-coquard@lyon.unicancer.fr. |
